total therapy 7: high response rates in high risk ndmm to daratumumab
Published 4 years ago • 134 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
2:46
managing patients with high-risk myeloma
-
5:07
daratumumab in the management of al amyloidosis
-
2:17
extended follow-up of the master trial
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
1:17
evaluating response to treatment in patients with emd
-
2:20
ultra high-risk myeloma
-
4:00
immunotherapies for the treatment of high-risk mm
-
8:13
treatment strategies for high-risk mm
-
2:15
vipor: a multi-targeted therapy for the treatment of r/r dlbcl
-
1:11
measuring treatment response rates in multiple myeloma
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
1:56
defining the optimal duration of maintenance therapy for multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
2:40
the role of consolidation therapy in mm and updates from the emn02 trial
-
1:01
car-t: myeloma toxicities
-
2:02
recent advances in all treatment
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma